State Street SPDR S&P Biotech ETF (XBI) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

State Street SPDR S&P Biotech ETF (XBI) Financial Services Profile

State Street SPDR S&P Biotech ETF (XBI) provides targeted exposure to the biotechnology sector of the S&P TMI, tracking a modified equal-weighted index. This ETF allows investors to strategically position themselves within the biotech industry, spanning large, mid, and small-cap stocks, offering a diversified yet focused investment vehicle.

What Is the Investment Thesis for XBI?

The State Street SPDR S&P Biotech ETF (XBI), with a market capitalization of $8.56B and a beta of 1.47, presents a targeted investment in the biotechnology sector. Its modified equal-weighted approach offers diversification across large, mid, and small-cap biotech companies. A key value driver is the potential for growth within the biotechnology industry, driven by innovation in drug development and increasing healthcare spending. Upcoming catalysts include potential breakthroughs in gene therapy and personalized medicine, which could significantly boost the valuations of companies within the index. However, potential risks include regulatory hurdles, clinical trial failures, and market volatility, all inherent to the biotech industry. Investors may want to evaluate these factors when evaluating XBI as part of their portfolio, recognizing the high-risk, high-reward nature of the biotechnology sector.

Based on FMP financials and quantitative analysis

XBI Key Highlights

Market Cap of $8.56B indicates substantial investment in the biotechnology sector through XBI.

• Beta of 1.47 suggests higher volatility compared to the overall market, typical for biotech investments.
• The ETF tracks the S&P Biotechnology Select Industry Index, providing focused exposure to the biotech industry.
• Modified equal-weighted index reduces concentration risk and allows exposure to smaller, high-growth biotech firms.
• No dividend yield reflects the growth-oriented nature of the biotechnology sector.

Who Are XBI's Competitors?

XBI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are XBI's Key Strengths?

Diversified exposure to the biotechnology sector.

• Modified equal-weighted methodology reduces concentration risk.
• High liquidity and trading volume.
• Strong brand recognition as part of the SPDR ETF family.

What Are XBI's Weaknesses?

High beta indicates higher volatility compared to the overall market.

• Sector-specific focus limits diversification.
• Performance is highly dependent on the biotechnology industry's performance.
• No dividend yield may deter income-seeking investors.

What Could Drive XBI Stock Higher?

Clinical trial results for key drug candidates within the ETF's holdings.

• Regulatory approvals for new therapies.
• Increasing healthcare spending and demand for innovative treatments.
• Mergers and acquisitions within the biotechnology sector.

What Are the Key Risks for XBI?

Clinical trial failures and regulatory setbacks.

• Market volatility and economic downturns.
• High research and development costs.
• Competition from other biotechnology companies.
• Changes in healthcare policy and reimbursement rates.

What Are the Growth Opportunities for XBI?

• Advancements in Gene Therapy: The gene therapy market is projected to reach $36.9 billion by 2030, driven by the potential to cure genetic diseases with single-dose treatments. XBI's holdings in companies pioneering gene therapy technologies position it to benefit from this growth. The timeline for realizing this opportunity depends on regulatory approvals and successful clinical trials, but the long-term potential is substantial.
• Personalized Medicine: The personalized medicine market is expected to reach $3.2 trillion by 2030, fueled by advancements in diagnostics and targeted therapies. XBI's exposure to companies developing personalized medicine solutions allows investors to capitalize on this trend. The adoption of personalized medicine is contingent on technological advancements and cost-effectiveness, but the potential for improved patient outcomes is driving its growth.
• Increasing Healthcare Spending: Global healthcare spending is projected to reach $10 trillion by 2026, driven by aging populations and increasing access to healthcare in emerging markets. XBI's investments in biotechnology companies position it to benefit from this increased spending. The timeline for realizing this opportunity is tied to healthcare policy changes and economic growth, but the long-term trend is favorable.
• Drug Development Innovation: The pharmaceutical industry is experiencing a surge in drug development innovation, with new therapies targeting previously untreatable diseases. XBI's holdings in companies engaged in drug discovery and development provide exposure to this innovation. The success of these companies depends on clinical trial outcomes and regulatory approvals, but the potential for significant returns is high.
• Mergers and Acquisitions: The biotechnology industry is characterized by frequent mergers and acquisitions, as larger companies seek to acquire innovative technologies and pipelines. XBI's holdings in smaller, high-growth biotech companies make it a potential target for acquisition. The timeline for M&A activity is unpredictable, but the potential for significant gains is a recurring theme in the biotechnology sector.

What Are XBI's Competitive Advantages?

• First-mover advantage in offering a biotechnology-focused ETF.
• Strong brand recognition as part of the SPDR ETF family.
• High liquidity and trading volume.
• Diversified exposure to the biotechnology sector.

What Does XBI Do?

The State Street SPDR S&P Biotech ETF (XBI) was created to replicate, before fees and expenses, the total return performance of the S&P Biotechnology Select Industry Index. This index represents the biotechnology sub-industry within the broader S&P Total Market Index (TMI). XBI provides investors with a means to access a basket of stocks specifically focused on biotechnology companies. The ETF employs a modified equal-weighting methodology, which differentiates it from market capitalization-weighted ETFs. This approach aims to reduce concentration risk by giving similar weight to companies regardless of their size, potentially offering exposure to smaller, high-growth biotech firms alongside established industry players. Since its inception, XBI has become a popular tool for investors seeking to express a view on the biotechnology sector. The fund's holdings span a range of companies involved in various aspects of biotechnology, including drug discovery, development, and manufacturing. By tracking the S&P Biotechnology Select Industry Index, XBI offers a relatively liquid and transparent way to invest in this dynamic and often volatile sector. The ETF's structure allows for both strategic, long-term investments and tactical, short-term positions, catering to a diverse range of investment strategies. State Street, the issuer of the SPDR ETFs, is one of the world's largest asset managers, providing investors with confidence in the fund's management and operational efficiency. XBI's focus on the biotechnology sector makes it a specialized tool within the broader landscape of sector-specific ETFs.

What Products and Services Does XBI Offer?

• Tracks the performance of the S&P Biotechnology Select Industry Index.
• Provides exposure to a diversified portfolio of biotechnology companies.
• Employs a modified equal-weighted methodology to reduce concentration risk.
• Offers investors a liquid and transparent way to invest in the biotech sector.
• Allows for both strategic, long-term investments and tactical, short-term positions.
• Provides access to companies involved in drug discovery, development, and manufacturing.

How Does XBI Make Money?

• Tracks the S&P Biotechnology Select Industry Index.
• Generates revenue through management fees charged to investors.
• Offers a diversified investment in the biotechnology sector through a single ETF.
• Utilizes a modified equal-weighted approach to mitigate concentration risk.

What Industry Does XBI Operate In?

The biotechnology industry is characterized by rapid innovation, high research and development costs, and significant regulatory oversight. The market is driven by advancements in genomics, personalized medicine, and novel drug therapies. The State Street SPDR S&P Biotech ETF (XBI) operates within this dynamic landscape, offering investors exposure to a broad range of companies, from established players to emerging innovators. Competitors like AIQ, BBIN, BBUS, EWZ, and FDL offer alternative approaches to investing in the biotechnology and related sectors, with varying degrees of diversification and focus.

Who Are XBI's Key Customers?

• Institutional investors seeking exposure to the biotechnology sector.
• Retail investors looking for a diversified investment in biotech stocks.
• Financial advisors seeking to allocate client portfolios to the biotech industry.
• Hedge funds and other sophisticated investors trading on short-term biotech trends.

XBI Valuation & Market Position

With a $8.56B market cap, State Street SPDR S&P Biotech ETF sits in the mid-cap segment of the market. Relative to its peer group, XBI's quantitative score of 47/100 is roughly in line with the peer average of 48/100.

Return on equity for State Street SPDR S&P Biotech ETF stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. XBI trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

XBI Financials

XBI Latest News

XBI Analyst Consensus

XBI MoonshotScore

What Investors Ask About State Street SPDR S&P Biotech ETF (XBI) — Financial Services

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources